14 results about "Amino acid binding" patented technology

The invention provides an application of polyphyllin VII in preparation of an Akt signaling pathway inhibitor targeting GRB2, the invention reveals that PPVII is specifically combined with GRB2 protein and regulates and controls the function of the GRB2 protein for the first time, the Akt pathway inhibition effect is exerted, and the molecular mechanism of PPVII is specifically shown as follows: molecular docking and dynamic simulation confirms that PPVII and an SH3 structural domain of GRB2 form a stable compound, and the stable compound is used for inhibiting the Akt pathway of the GRB2. And the key amino acid binding sites are Ile65, Gln157, Tyr160 and Phe182. Cell thermal transfer experiments (CETSA) show that PPVII can significantly enhance the thermal stability of GRB2 protein, surface plasmon resonance (SPR) determines the direct binding affinity KD = 58.5 [mu] M, functional research proves that PPVII inhibits an Akt signal channel through a GRB2 dependency mode, the polyphyllin VII is used as a GRB2 targeted inhibitor, and by specifically binding with an SH3 structural domain of GRB2 and inhibiting a downstream Akt signal channel, the polyphyllin VII can be used for inhibiting the Akt signal channel in the GRB2 targeted inhibitor. And a new strategy and a candidate compound are provided for intervention of related diseases.

The invention provides a preparation method of an amino acid liquid fertilizer, and relates to the technical field of amino acid liquid fertilizers. According to the preparation method of the amino acid liquid fertilizer, the amino acid liquid fertilizer is prepared from the following raw materials in parts by mass: 550-650 parts of a nutrient solution, 350-400 parts of liquid amino acid, 60-70 parts of boric acid, 50-60 parts of zinc sulfate and 5-6 parts of a root growth promoting agent. The amino acid is combined with the boric acid and the zinc sulfate, and then is combined with the root growth promoting agent, so that the liquid fertilizer capable of meeting the crop rooting requirement can be prepared, and the defects that the liquid fertilizer applied in the existing production is low in amino acid, boron and zinc content, cannot completely meet the requirements of crop growth and is short in fertilizer efficiency lasting period are overcome. Amino acid is used as a main material and matched with other boron and zinc elements to be fully dissolved, auxiliaries are added, crops can better absorb the amino acid, boron and zinc for use, the utilization rate is increased, plant growth is promoted, the crop yield is improved, and precise application of water and fertilizer integration is matched.

Obtained is: a method for efficiently producing a polypeptide containing a non-canonical amino acid; a method for incorporating a non-canonical amino acid into a polypeptide; a method for producing tRNA bound to a non-canonical amino acid; a non-canonical amino acid incorporation system; a material for use in these methods; or the like. Used is a method for producing a polypeptide containing a non-canonical amino acid, comprising: a step of contacting PylRS from an organism belonging to the order Methanomassiliicoccales or Thermoplasmatales with the non-canonical amino acid; and an incorporation step selected from step (a) of incorporating the non-canonical amino acid into the polypeptide with higher efficiency than in a case of using a cell-free protein synthesis system with PylRS of Methanosarcina mazei (MmPylRS) or step (b) of incorporating the non-canonical amino acid into the polypeptide with higher efficiency than in a case of using an Escherichia coli protein synthesis system with a vector carrying a gene for the PylRS under regulation by a glmS promoter or a case of using an Escherichia coli protein synthesis system with a vector carrying a gene for the PylRS under regulation by a glnS promoter. Alternatively, used is a non-canonical amino acid incorporation system containing highly concentrated PylRS from an organism belonging to the order Methanomassiliicoccales or Thermoplasmatales.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.

The present invention provides methods for identifying and sequencing proteins, polypeptides, and amino acids, as well as compositions useful for them. [Solution] The present invention provides amino acid recognition molecules, such as amino acid-binding proteins and their fusion polypeptides, which differentially associate with different types of amino acids to generate detectable characteristic signatures that serve as indicators of the amino acid sequence of polypeptides. The present invention also provides amino acid recognition molecules that include a shielding element to enhance photostability during polypeptide sequencing reactions.

The invention provides a covalent small molecule compound and application and a pharmaceutical composition thereof, and relates to the technical field of pharmaceutical chemistry. The covalent small molecule compound provided by the invention can be combined with specific amino acid in the schistosome to form a covalent bond so as to inhibit the biological function of the schistosome. The covalent small molecule compound provided by the invention has a good killing effect on schistosomiasis and adult schistosomiasis, can be used for preparing drugs for treating schistosomiasis, and overcomes the technical problem of poor curative effect or ineffective treatment caused by drug resistance generated by long-term use of existing anti-schistosomiasis drugs; important scientific basis and research value are provided for research and development of novel anti-schistosomiasis drugs. The result of the embodiment shows that the insect reduction rate of the covalent small molecule compound provided by the invention can reach 82.35% (superior to praziquantel) in the juvenile insect stage, the insect reduction rate of the covalent small molecule compound in the adult stage can reach 63.63%, and the covalent small molecule compound shows relatively high activity of killing schistosome in vivo.

Provided herein are binding agents that selectively bind to individual monomer types (e.g., amino acid types) of a polymeric analyte (e.g., a peptide). The present disclosure provides methods for producing and, optionally, engineering binding agents. Such binding agents can be used for a variety of applications, including single-molecule peptide or protein sequencing.

There is provided a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) at least one sumoylated lysine residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said sumoylated lysine residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs. Also provided is a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) a C-terminal aspartic acid residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said C-terminal aspartic acid residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs.

N-terminal amino acid binding (NAAB) reagents are a tool for parallel, high-throughput proteomics. A fluorescently-labeled NAAB allows immobilized peptides to be identified by their N-terminal residues using single-molecule fluorescent microscopy, which enables novel proteomic analysis, like fluorescence-based next-generation protein sequence. Amino acid-specific binders are presented which bind to leucine at the N-terminus of peptides / polypeptides / proteins with high affinity and specificity, allowing detection of an N-terminal leucine with high confidence.

Provided herein are novel amino acid binding proteins that recognize aspartate and / or glutamate in protein sequencing reactions; novel amino acid binding proteins that recognize arginine in protein sequencing reactions; and novel amino acid binding proteins that recognize glycine, alanine, and / or serine in protein sequencing reactions.

Provided herein are novel amino acid binding proteins that recognize aspartate and / or glutamate in protein sequencing reactions; novel amino acid binding proteins that recognize arginine in protein sequencing reactions; and novel amino acid binding proteins that recognize glycine, alanine, and / or serine in protein sequencing reactions.

The invention discloses an application of ganoderic acid A as an intestinal farnesic acid X receptor (FXR) inhibitor in preparation of a product for preventing and / or treating hyperlipidemia. Molecular docking software is used for predicting that ganoderic acid A can be combined with FXR and occupies an active site of the FXR, and a possible amino acid binding site is a TYR (tyrosine) 369 amino acid residue; the application of a Caco2 cell model proves that the ganoderic acid A can penetrate through a cell membrane to be directly combined with the FXR in the cell; a surface plasmon resonance result proves that ganoderic acid A can competitively inhibit the combination of an FXR endogenous agonist and FXR so as to inhibit the activity of the FXR endogenous agonist. By inhibiting the activity of FXR, the ganoderic acid A can significantly inhibit the expression of intestinal FXR target gene ileum bile acid binding protein, fibroblast growth factor 15 and small heterodimer partner, and effectively improve C57BL / 6J mouse hyperlipidemia induced by high fat diet.

To provide use of an elder berry extract for preventing or treating muscle diseases.SOLUTION: Provided is a pharmaceutical composition for preventing or treating a muscle disease, comprising, as an active ingredient, a monosaccharide and amino acid-bound compound or a pharmaceutically acceptable salt thereof, the monosaccharide and amino acid-bound compound being a compound represented by the following formula and the like, and the muscle disease being a disease caused by muscle loss.SELECTED DRAWING: Figure 17

The invention relates to the field of developing agents, in particular to a fingerprint developing agent and a developing method and application thereof. Wherein the fingerprint developing agent comprises a compound I and an organic solvent; the molecular structural formula of the compound I is I; wherein X is selected from CH3O <->,-CH3,-CH2CH3 or NO2; y is selected from CH3O <->,-CH3,-CH2CH3, NO2 or halogen; x and Y are the same or different. Compared with a traditional fingerprint display method, the compound can realize higher sensitivity and clearer imaging effect; and only protein and amino acid in fingerprints are combined to form a fluorescent product, and other substances (such as paper and the like) do not have a showing effect, so that highly selective fingerprint showing can be realized. And the method has a good application value in the actual development of the developing reagent.